Brick building with tall windows and letters in front that say "Food and Drug Administration"
FDA Limits Use of J&J Vaccine, Citing Safety Concerns
US adults are now only eligible for the vaccine under certain circumstances.
ABOVE: ©, Grandbrothers
FDA Limits Use of J&J Vaccine, Citing Safety Concerns
FDA Limits Use of J&J Vaccine, Citing Safety Concerns

US adults are now only eligible for the vaccine under certain circumstances.

US adults are now only eligible for the vaccine under certain circumstances.

ABOVE: ©, Grandbrothers


A masked doctor in a white coat and blue gloves administers a vaccine into the arm of a masked child.
Pfizer Vaccine Less Protective for Younger Kids: Preprint
Dan Robitzski | Feb 28, 2022
The vaccine’s effectiveness in children ages 5 to 11 rapidly declined over the course of a month, according to new research that looked at the health outcomes of hundreds of thousands of children in New York during the Omicron surge.
People waiting in line for COVID Vaccine
CDC: COVID-19 Booster Effectiveness Wanes After Four Months
Natalia Mesa | Feb 14, 2022

The agency also finds that third shots prevented hospitalizations during the Omicron wave.

Several silver foil pill packs with white pills
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
Jef Akst | Dec 23, 2021
Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.
man in white with bookshelves
Medical Researcher and Philanthropist Laszlo Bito Dies at 87
Chloe Tenn | Dec 2, 2021
His work contributed to the development of the drug Xalatan, a treatment for glaucoma.
building sign
Johnson & Johnson Vaccine Garners First Full Approval
Chloe Tenn | Nov 24, 2021
Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.
adolescent getting vaccination shot
Moderna Vaccine Paused for Young People in Two European Countries
Chloe Tenn | Oct 6, 2021
Health authorities in both countries announced that people under certain age cutoffs are now ineligible for the Spikevax COVID-19 shot due to its association with heart inflammation.
moderna and pfizer vaccine vials
Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?
Alejandra Manjarrez | Sep 24, 2021
Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.  
photograph of a syringe and vial of colorless liquid
FDA Approves Pfizer-BioNTech COVID-19 Vaccine
Annie Melchor | Aug 23, 2021
The milestone marks the first fully-approved COVID-19 vaccine in the United States.
COVID-19 vaccine vials on a map of the world indicating inequitable distribution
Wealthier Nations Disregarding WHO Call for COVID-19 Booster Moratorium
Christie Wilcox | Aug 5, 2021
The organization implored nations to wait on booster shots until the global vaccination rate increases, but several of the world’s more well-off countries have expressed their intentions to offer them regardless.
cartoon of a scientist holding a magnifying glass up to test tubes of blood
How the Second mRNA Vaccine Bolsters Immunity
Annie Melchor | Jul 23, 2021
A study looks beyond T and B cell responses to show how the Pfizer COVID-19 vaccine elicits a strong innate immune response.
pregnancy pregnant covid-19 coronavirus pandemic sars-cov-2 vaccine immunization moderna mrna pfizer/biontech
COVID-19 Vaccines Appear Safe During Pregnancy: Early Data
Christie Wilcox | Apr 22, 2021
Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.
an illustration of a blood vessel with clumped-together blood cells inside
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Shawna Williams | Apr 16, 2021
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.
lymph node germinal center antibody covid-19 sars-cov-2 pandemic coronavirus plasmablast b cell pfizer vaccine immunity
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
Katarina Zimmer | Mar 25, 2021
In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.
COVID-19, SARS-CoV-2, coronavirus, pandemic, vaccine, vaccine trials, combination, mix and match, immunity, antibodies, T cells, Pfizer, Moderna, AstraZeneca, clinical trials
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
COVID-19, SARS-CoV-2, Johnson & Johnson, Pfizer, Moderna, vaccine, vaccination, variant, FDA
US Authorizes a Third COVID-19 Vaccine
Asher Jones | Mar 1, 2021
Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.
COVID-19, coronavirus, SARS-CoV-2, pandemic, virus, vaccine, vaccination, Pfizer, AstraZeneca
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
Asher Jones | Feb 23, 2021
Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.
Pfizer, SARS-CoV-2, COVID-19, pandemic, coronavirus, vaccine, vaccination, Israel, B.1.1.7, B.1.351, variant, disease
Pfizer’s COVID-19 Vaccine Reduces Viral Load: Study
Asher Jones | Feb 10, 2021
Preliminary results from an Israel-based study suggest that one dose of the vaccine reduces infectiousness—a key factor in slowing virus spread.
SARS-CoV-2, COVID-19, coronavirus, pandemic, virus, vaccine, vaccination, outbreak, infectious disease, Johnson & Johnson, Moderna, Pfizer, drug development
One-Shot COVID-19 Vaccine Prevents Severe Disease
Asher Jones | Jan 29, 2021
Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Max Kozlov | Nov 9, 2020
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.